STAAR Surgical Company
STAA Healthcare Medical Instruments & Supplies
In the quarter to June 2026, revenue grew 111.0%, EPS grew 147.1% and free cash flow grew 166.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow STAA
STAAR Surgical Company (STAA) Altman Z-score
STAAR Surgical Company's Altman Z-score for fiscal 2025 is 6.44, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 6.44 | (1.00) |
| FY2024 | 7.43 | (2.86) |
| FY2023 | 10.30 | (8.14) |
| FY2022 | 18.44 | (12.52) |
| FY2021 | 30.96 | (5.85) |
| FY2020 | 36.81 | 16.34 |
| FY2019 | 20.47 | (3.33) |
| FY2018 | 23.81 | 10.10 |
| FY2017 | 13.70 | 6.44 |
| FY2016 | 7.26 | 2.01 |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.54 | — | 0.65 | |
| Retained earnings / total assets | (0.33) | — | −0.46 | |
| EBIT / total assets | (0.20) | — | −0.67 | |
| Market value of equity / total liabilities | 10.65 | — | 6.39 | |
| Sales / total assets | 0.53 | — | 0.53 | |
| Altman Z-score | Safe zone | 6.44 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 4.46 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NNNN Anbio Biotechnology compare | 8,977× |
| ATRC AtriCure, Inc. compare | 7.3× |
| LMAT LeMaitre Vascular, Inc. compare | 7.0× |
| STAA STAAR Surgical Company | 6.4× |
| KMTS Kestra Medical Technologies, Ltd. compare | 3.9× |
| AZTA Azenta, Inc. compare | 3.9× |
| ANGO AngioDynamics, Inc. compare | 1.6× |
| XRAY DENTSPLY SIRONA Inc. compare | 0.5× |
| AVR Anteris Technologies Global Corp. compare | −31.5× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets